<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02845063</url>
  </required_header>
  <id_info>
    <org_study_id>W 549 ACE-REHAB</org_study_id>
    <secondary_id>KEK-ZH-Nr. 2014-0319</secondary_id>
    <nct_id>NCT02845063</nct_id>
  </id_info>
  <brief_title>Effect of ACE Genotype on Cardiovascular Rehabilitation</brief_title>
  <acronym>ACE-REHAB</acronym>
  <official_title>Effects of ACE Genotype on Muscular and Functional Adaptations Following a Cardiovascular Rehabilitation Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Balgrist University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Balgrist University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to systematically investigate the interaction between training modality, ACE
      genotype and disease in heart patients whom complete a cardiovascular rehabilitation program.
      This is carried out with the goal to improve the benefit of cardiovascular rehabilitation for
      the patient by maximising adjustments in muscle structure and function with the intervention.
      A population of healthy individuals will be recruited who will carry out the same training
      program, in order to compare the training effects respective to the general population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacological inhibition of angiotensin converting enzyme modifies exercise-induced
      pro-angiogenic and mitochondrial gene transcript expression. Exercise-induced muscle
      plasticity importantly interacts with the insertion/deletion genotype of ACE and the training
      modality and intensity. The aim of this study is to systematically investigate the
      interaction between training modality, ACE genotype and disease in heart patients whom
      complete a cardiovascular rehabilitation program.

      There are two training modalities being used: The first modality involves cardiovascular
      training by an interval type of protocol that includes a high repetition number of shortening
      (i.e. concentric) type contractions on a softrobotic device. The second modality includes a
      high repetition number of lengthening (i.e. eccentric) type contractions on a softrobotic
      device. In both training modalities the same muscle groups are exercised over the same range
      of motion, with the same speed of movement, but with widely differing pedal force. Total
      absolute external mechanical work will be matched.

      In order to assess the baseline values and the effect size of the muscle and training
      adjustments made, healthy male and female volunteers will be included who are matched with
      respect to age and sex to the patient population and undergo the same training program.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ACE I/D genotype</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>Genotype of the assessed insertion/deletion gene polymorphism of angiotensin converting enzyme ACE, i.e. ACE-II, ACE-ID or ACE-DD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Molecular muscle characteristics - mRNA</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• mRNA expression of VEGF, HIF-1a, HIF-1b, tenascin-C, Angpt1, Angpt1R, neuropilin, midkine, restin, COX4-1, COX4I-2, CPTI, LPL, LIPE, FATP, CD36 [relative expression per 28S rRNA]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Molecular muscle characteristics- protein</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Protein content of FAK, FRNK, p70S6K, mTOR, JNK, NDUFA9, SDH, UQCRC1, COX4I1, COX4I2, ATP5A1, VEGF, HIF-1a, CD31, MHC-1, MHC-2A, MHC-2X, MyoD, myogenin, CaMKII [pixel counts per actin]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Molecular muscle characteristics- phosphorylation</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Phosphorylation of proteins phospho-Y397- FAK, phospho-T421/S424-P70S6K, phospho -T183/Y185-JNK, phospho-S2448-mTOR [pixel counts per actin]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Molecular muscle characteristics- ACE</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• ACE activity [fmol min-1]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cellular muscle characteristics - fiber type %</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Distribution of type I, IIA and IIX fibers [%]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cellular muscle characteristics - fiber area %</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Area percentage of type I, IIA and IIX fibers [% area]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cellular muscle characteristics - fiber type CSA</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Cross sectional area of type I, IIA and IIX fibers [micrometer2]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cellular muscle characteristics - Capillary density</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Capillary density [capillaries micrometer-2]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cellular muscle characteristics - Capillary-to-fiber ratio</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Capillary-to-fiber ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional muscle characteristics - Maximal Power</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Maximal power during ramp test on ergometer [Watt]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional muscle characteristics - Critical Power</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Critical power in ramp test on ergometer [Watt]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional muscle characteristics - Real Power</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Real Power as estimated on the soft robotic device [Watt]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional muscle characteristics - Reactive Power</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Reactive Power as estimated on the soft robotic device [Watt]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional muscle characteristics - Negative Power</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Negative Power as estimated on the soft robotic device [Watt]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional muscle characteristics - Maximal force</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Maximal force during the reactive power test on the soft robotic device [Newton]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional muscle characteristics - Maximal velocity</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Maximal velocity during the reactive power test on the soft robotic device [m sec-1]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional muscle characteristics - Rate of force development</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Rate of force development as estimated during the Real Power test on the soft robotic device [meter sec-2]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle metabolism - muscle oxygenation ramp</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Muscle oxygenation (m. vastus lateralis, m. gastrocnemius, m. gluteus maximus) during ramp test on ergometer [%]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle metabolism - muscle oxygenation robot exercise</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Muscle oxygenation (m. vastus lateralis, m. gastrocnemius, m. gluteus maximus) during exercise on soft robot [%]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle metabolism - hemoglobin ramp</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Total hemoglobin during ramp test on ergometer [%]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle metabolism - hemoglobin robot exercise</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Total hemoglobin during exercise on soft robot [%]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle metabolism - lipid compounds</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Concentration of lipid compounds in m. vastus lateralis muscle during exercise on soft roboter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle metabolism - metabolites</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Concentration of metabolites in m. vastus lateralis muscle during exercise on soft roboter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle metabolism - serum glucose</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Concentration of glucose in serum during ramp test on ergometer [mmol l-1]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle metabolism - serum lactate</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Concentration of lactate in serum during ramp test on ergometer [mmol l-1]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular function - Heart rate rest</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Heart rate at rest [beats per minute]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular function - Heart rate ramp</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Heart rate in ramp test on ergometer [beats per minute]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular function - cardiac output</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Cardiac output [L min-1]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular function - ejection fraction</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Ejection fraction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular function - Maximal oxygen uptake</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Maximal oxygen uptake (VO2max) during ramp test on ergometer [ml O2 min-1 kg-1]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular function - ventilation</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Ventilation during ramp test on ergometer [L min-1]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular function - ventilation frequency</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Ventilation frequency ramp test on ergometer [min-1]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular function - respiration quotient</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>• Respiration quotient during ramp test on ergometer [ L O2 inspired / L CO2 expired]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular function - endurance</measure>
    <time_frame>975 days: May 2016-January 2019</time_frame>
    <description>Time-to-exhaustion in constant load on ergometer [seconds]</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>concentric cardiovascular rehabilitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Heart patients under ACE inhibitor intake will be enrolled in the intervention 'concentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'</description>
  </arm_group>
  <arm_group>
    <arm_group_label>eccentric cardiovascular rehabilitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Heart patients under ACE inhibitor intake will be enrolled in the intervention 'eccentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'</description>
  </arm_group>
  <arm_group>
    <arm_group_label>concentric cardiovascular training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy subjects will be enrolled in the intervention 'concentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'</description>
  </arm_group>
  <arm_group>
    <arm_group_label>eccentric cardiovascular training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy subjects will be enrolled in the intervention 'eccentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>concentric cardiovascular training</intervention_name>
    <description>Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of concentric type contractions on a softrobotic device.</description>
    <arm_group_label>concentric cardiovascular rehabilitation</arm_group_label>
    <arm_group_label>concentric cardiovascular training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>eccentric cardiovascular training</intervention_name>
    <description>Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of eccentric type contractions on a softrobotic device.</description>
    <arm_group_label>eccentric cardiovascular rehabilitation</arm_group_label>
    <arm_group_label>eccentric cardiovascular training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ACE genotyping</intervention_name>
    <description>Subjects will be genotyped for the ACE-I/D gene polymorphism.</description>
    <arm_group_label>concentric cardiovascular rehabilitation</arm_group_label>
    <arm_group_label>eccentric cardiovascular rehabilitation</arm_group_label>
    <arm_group_label>concentric cardiovascular training</arm_group_label>
    <arm_group_label>eccentric cardiovascular training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patient group inclusion criteria:

          -  stable coronary heart patients/heart patients without ischemia

          -  Left ventricular ejection fraction &gt; 50%

          -  Drug therapy with ACE inhibitors

          -  V̇O2peak &lt;86% of the medical reference value Voluntary participation

          -  Written informed consent of the subject to participate in the study

        exclusion criteria:

          -  relevant valvular heart disease

          -  arterial hypertension (blood pressure at rest&gt; 140/90)

          -  arrhythmogenic cardiomyopathy

          -  ACE inhibitor intolerance

          -  contraindication for ethical reasons

          -  known or suspected non-compliance with the curriculum

          -  smoker

          -  drug or alcohol disease

          -  inability of the patient to follow the study procedures (e.g. because of language
             problems, mental illness, dementia)

          -  participation in another clinical trial within the last 30 days prior to confinement
             and during the study

          -  other, clinically significant comorbidities (cardiac arrhythmia, renal insufficiency,
             hepatic dysfunction, connective tissue disease [Marfan syndrome, Ehlers-Danlos
             syndrome])

        Healthy subject group inclusion criteria:

          -  inconspicuous ECG under exercise (persons in whom the exercise ECG is abnormal will be
             referred for a cardiological evaluation recessed to the University Hospital Zurich)

          -  V̇O2peak &lt;50 ml O2 min-1 kg-1

          -  Voluntary participation

          -  Written informed consent of the subject to participate in the study

        exclusion criteria:

          -  relevant valvular heart disease

          -  arterial hypertension (blood pressure at rest&gt; 140/90)

          -  arrhythmogenic cardiomyopathy

          -  ACE inhibitor intolerance

          -  contraindication for ethical reasons

          -  known or suspected non-compliance with the curriculum

          -  smoker

          -  drug or alcohol disease

          -  inability of the patient to follow the study procedures (e.g. because of language
             problems, mental illness, dementia)

          -  participation in another clinical trial within the last 30 days prior to confinement
             and during the study

          -  other, clinically significant comorbidities (cardiac arrhythmia, renal insufficiency,
             hepatic dysfunction, connective tissue disease [Marfan syndrome, Ehlers-Danlos
             syndrome])
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter O Frey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Balgrist University Hospital, Move&gt;med, Swiss Olympic Center, Zurich, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian M Schmied, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology, University Hospital Zurich, Zurich, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Flück, PhD</last_name>
    <phone>+41 44 386 3791</phone>
    <email>mflueck@research.balgrist.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marco Toigo, PhD</last_name>
    <phone>+41 44 386 3791</phone>
    <email>mtoigo@research.balgrist.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Balgrist University Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Flück, PhD</last_name>
      <phone>+41445107350</phone>
      <email>mflueck@research.balgrist.ch</email>
    </contact>
    <contact_backup>
      <last_name>Marco Toigo, PhD</last_name>
      <phone>+41445107351</phone>
      <email>mtoigo@research.balgrist.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian M Schmied, MD</last_name>
      <phone>+41 44 255 3478</phone>
      <email>Christian.Schmied@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>David Niederseer, MD</last_name>
      <phone>+41 44 255 1111</phone>
      <email>david.niederseer@usz.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://dx.doi.org/10.4172/2161-0940.S5-005</url>
    <description>Mathes et al, 2015</description>
  </link>
  <link>
    <url>http://dx.doi.org/10.1016/j.atg.2015.03.002</url>
    <description>van Ginkel et al, 2015</description>
  </link>
  <reference>
    <citation>van Ginkel S, Ruoss S, Valdivieso P, Degens H, Waldron S, de Haan A, Flück M. ACE inhibition modifies exercise-induced pro-angiogenic and mitochondrial gene transcript expression. Scand J Med Sci Sports. 2016 Oct;26(10):1180-7. doi: 10.1111/sms.12572. Epub 2015 Sep 26.</citation>
    <PMID>26407530</PMID>
  </reference>
  <reference>
    <citation>van Ginkel S, Amami M, Dela F, Niederseer D, Narici MV, Niebauer J, Scheiber P, Müller E, Flück M. Adjustments of muscle capillarity but not mitochondrial protein with skiing in the elderly. Scand J Med Sci Sports. 2015 Aug;25(4):e360-7. doi: 10.1111/sms.12324. Epub 2014 Sep 28.</citation>
    <PMID>25262765</PMID>
  </reference>
  <reference>
    <citation>Mathes S, van Ginkel SL, Vaughan D, Valdivieso P, Flück M, Gene-pharmacologial effects on exercise-induced muscle gene expression in healthy men. Anat Physiol 2015, S5.</citation>
  </reference>
  <reference>
    <citation>van Ginkel S, de Haan A, Woerdeman J, Vanhees L, Serné E, de Koning J, Flück M. Exercise intensity modulates capillary perfusion in correspondence with ACE I/D modulated serum angiotensin II levels. Appl Transl Genom. 2015 Mar 27;4:33-7. doi: 10.1016/j.atg.2015.03.002. eCollection 2015 Mar.</citation>
    <PMID>26937347</PMID>
  </reference>
  <reference>
    <citation>Vaughan D, Huber-Abel FA, Graber F, Hoppeler H, Flück M. The angiotensin converting enzyme insertion/deletion polymorphism alters the response of muscle energy supply lines to exercise. Eur J Appl Physiol. 2013 Jul;113(7):1719-29. doi: 10.1007/s00421-012-2583-6. Epub 2013 Feb 9.</citation>
    <PMID>23397151</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2015</study_first_submitted>
  <study_first_submitted_qc>July 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2016</study_first_posted>
  <last_update_submitted>August 6, 2016</last_update_submitted>
  <last_update_submitted_qc>August 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>muscle plasticity</keyword>
  <keyword>exercise</keyword>
  <keyword>rehabilitation</keyword>
  <keyword>perfusion</keyword>
  <keyword>ACE</keyword>
  <keyword>genotype</keyword>
  <keyword>hypertension</keyword>
  <keyword>molecular biology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

